OSF Ventures, OSF Healthcare's corporate venturing unit, has backed healthcare-focused VC firm LRVHealth's fourth fund, which had set a $100m target for close.

Eric Steager, formerly managing director at Independence Blue Cross’ Strategic Innovation Portfolio unit, has taken a vice-president of corporate venture capital position at Anthem.

Smith & Nephew and Johnson & Johnson have exited the shoulder implant developer in an all-cash acquisition by Stryker that could reach $220m.

TAU-founded Qart Medical has been backed by the university’s Technology Innovation Momentum Fund and Chartered Investment Managers, itself a partner in TAU Ventures.

Embattled commercialisation firm NetScientific is closing two medical diagnostics spinouts from UCLA after both failed to attract external funding.

Alcon acquired the intraocular lens developer in a $285m deal that follows $106m in funding from investors including its parent company Novartis as well as Johnson & Johnson and Medtronic.

The sickle cell disease therapy developer boosted its overall funding to $94m in a round backed by Lundbeck, Pfizer and Alexandria Real Estate Equities.

CWRU-licensed NervGen Pharma floated at the top of its range on the TSX Venture Exchange, with the proceeds earmarked to push its lead candidate for spinal cord injury into the clinic.

Cystic fibrosis drug developer Respirion Pharmaceuticals has spun out from Telethon Kids Institute with capital from an Australian government-backed initiative.

The central nervous system disorder drug developer has now raised more than $118m, with PureTech Health and Pivotal BioVenture Partners among the investors in its latest round.